Vaccination of BALB/c mice with Leishmania donovani derived lipophosphoglycan does not conver cross-protection to L. major infections

East African Medical Journal

Volumn 80, Issue 5, 2003, Pages 260-263

  Tonui, W K ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSPHINGOLIPID; LIPOPHOSPHOGLYCAN; VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; COMPARATIVE STUDY; CROSS REACTION; DISEASE MODEL; IMMUNOLOGY; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MOUSE; REFERENCE VALUE; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

ANIMALS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; GLYCOSPHINGOLIPIDS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; REFERENCE VALUES; TREATMENT OUTCOME; VACCINES;

EID: 23944463538     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mutinga, M.J and Ngoka, J.K. Investigations of animal reservoirs of Visceral Leishmaniasis and the isolation of Leishmania Major in Marigat, Baringo District, Kenya Insect Sci. Appl. 1983; 4:237-240.
2. Mutinga, M.J and Mngola E.N. Alternate treatment of Cutaneous leishmaniasis in Kenya. East Afr. Med. J. 1974; 5:68-78.
3. Handman, E. Leishmaniasis. Current status of vaccine development. Clin. Microbial. Rev. 2001; 14:229-243.
4. Veras, P., Brodskyn, C., Balestieri, F., et al. dhfr-ts-Leishmania major knockout mutant crossprotects against Leishmania amazonensis. Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 1999; 94:491-496.
5. Rachamin, N. and Jaffe, C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 1993; 150:2322-2331.
6. Gicheru, M.M., Olobo, J.O. and Anjili, C.O. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp. Parasitol. 1997; 85:109-116.
7. Mitchell G.F. and Handman, E. Heterologous protection in murine cutaneous leishmaniasis. Immunol. Cell. Biol. 1987; 65:387-392.
8. Bebars, M.A., el Serougi, A.O., Makled, K.M. An experimental vaccine providing heterologous protection for Leishmania species in murine model. J. Egypt Soc. Parasitol, 2000; 30:137-156.
9. Satti, I.N., Osman, H.Y., Daifalla, N.S., et al. Immunogenicity and safety of autoclaved Leishmania Major plus BCG vaccine in healthy Sudanese volunteers. Vaccine. 2001; 19(15-16):2100-2106.
10. Jensen, A.T., Ismail, A., Gaafar, A., El Hassan, A.M., Theander, T.G. Humoral and cellular immune responses to glucose regulated protein 78 - a novel Leishmania donovani antigen. Trop. Med. Int. Health. 2002; 7:471-476.
11. Turco, S.J. The lipophosphoglycan of Leishmania. Parasitol. Today. 1988; 4:255-257.
12. McNeely, T.B. and P.S. Doyle. Isolation of lipophosphoglycan from Leishmania donovani amastigotes. Arch. Biochem. & Biophy. 1996; 334:1-8.
13. Handman, E. and Mitchel, G.F. Immunization with Leishmania receptor for macrophages protective against cutaneous leishmaniasis. Proc. Nat. Acad. Sci. USA., 1985; 82: 5910-5914.
14. McConville, M.J., Bacic, A., Mitchell, G.F. and Handman, E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contain an alkyglycerophospholinositol lipid anchor. Proc. Nat. Acad.Sc. USA., 1987; 84:8941-8945.
15. Russell, D.G. and Alexander, J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted in liposomes. J. Immunol, 1988; 140:1274-1279.
16. Elhay, M., Kelleher, M., Bacic, A., et al. Lipophosphoglycan expression and virulence in Ricin-resistant variants of Leishmania major. Mol. Biochem. Parasitol. 1990; 40: 255-268.
17. Kemp, M., Theander, T.G. Handman, E, et al. Activation of human T lymphocytes by Leishmania lipophosphoglycan. Scan. J. Immunol. 1991; 33:219-224.
18. Mendonca, S.C, Russell, D.G. and Coutinho, S.G. Analysis of the human T cell responsiveness to purified antigens of Leishmania; lipophosphoglycan (LPG) and glycoprotein (GP63). Clin. Exp. Immunol. 1991; 83:472-478.
19. Tonui, W.K., Mpoke, S.S., Orago, A.S., Turco S.J., Mbati, P.A. and Mkoji, G.M. Leishmania donovani-derived lipophosphogycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamster (Mesocricetus auratus) and BALB/c mice against Leishmania donovani. 2002.(Manuscript in preparation).
20. Orlandi, P.A. and Turco, S.J. Structure of the lipid moiety of Leishmania donovani lipophosphoglycan. J. Biol. Chem. 1987; 262:10384-10391.
21. Handman, E., Symons, F.M., Balwia, T.M., Curtis, J. and Scheerlinck, J.P.Y. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th 1 type of immuneresponse. Infect. Immun. 1995; 63(11):4261-4267.
22. Yang, D.M., Rogers, M.V. and Liew, F.Y. Identification and characterization of host- protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunol. 1991; 72:3-9.
23. Voller, A, Bartlett, A. and Bidwell, D.E. Enzyme linked immunoassays for parasitic disease. Trans. Roy Soc. Trop. Med. Hyg. 1976; 70:98-106.
24. Tonui, W.K., Mbati, P.A., Anjili, C.O. et al. Transmission blocking vaccine studies in leishmaniasis: Lipophosphoglycan is a promising transmission blocking vaccine candidate against cutaneous leishmaniasis. East. Afr. Med. J. 2001; 78:84-89.
25. Gicheru, M., Olobo, J., Anjili, C., Orago, A.S., Modabber, F. and Scott, P. Vervet monkeys vaccinated with killed Leishmania major parasites and Interleukin-12 develop a Type 1 immune response but are not protected against infection challenge. Infect. immun. 2001; 69:245-251.
26. Beach, R., Kiilu, G., Hendricks, L.D., Oster, C.N. and Leeuwenburg, J. Cutaneous leishmaniasis: transmission of Leishmania major to man by the bite of naturally infected Phlebotomus duboscqi. Trans. Roy. Soc. Trop. Med. & Hyg. 1984; 78:747-751.
27. Mbati, P.A., Anjili, C.O., Lugalia, R., et al. Experimental immunization against cutaneous leishmaniasis using Leishmania major subcellular fractions alone or in combination with Phlebatomus duboscqi gut antigens. East. Afr. Med. J. 1995; 72:519-522.
28. Chulay, J.D. and Brycesson, A.D.M. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Amer. J. Trop. Med. Hyg., 1983; 32:475-479.
29. McConville, M.J, Turco, S.J., Ferguson, M.A. and Sacks, D.L. Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J. 1992; 11:3593-3600.
30. Turco, S.J, Hull, S.R., Orlandi, P.A. Jr, et al. Strucure of the major carbohydrate fragment of the Leishmania donovani lipophosphoglycan. Biochem. 1987; 26:6233-6238.